Raymond James & Associates »

Travere Therapeutics shares owned by Raymond James & Associates

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by Raymond James & Associates from 13F filings

Historical chart of Raymond James & Associates investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Raymond James & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Raymond James & Associates

Quarter filed Position value Share count Share price at filing
2024-09-30 $155k 11k 13.99

More positions owned by Raymond James & Associates

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Ishares Tr Core Msci Eafe (IEFA)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core S&p Mcp Etf (IJH)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Home Depot (HD)
UnitedHealth (UNH)

View all positions for Raymond James & Associates

Top funds holding Travere Therapeutics

BlackRock
BlackRock
Armistice Capital
Deep Track Capital
Vanguard Group
Rock Springs Capital Management
Macquarie Group
Woodline Partners
State Street Corporation
Morgan Stanley
Kynam Capital Management
Emerald Advisers
Renaissance Technologies
D. E. Shaw & Co
Bank of America Corporation

View all funds holding Travere Therapeutics